Last reviewed · How we verify
Aminolevulinic acid topical solution 20%
Aminolevulinic acid topical solution 20%, developed by George Washington University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Aminolevulinic acid topical solution 20% |
|---|---|
| Also known as | Levulan Kerastick |
| Sponsor | George Washington University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp (PHASE3)
- Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities (PHASE3)
- PDT vs Peels for Treatment of Actinic Keratoses (PHASE2)
- Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC) (PHASE2)
- Photodynamic Therapy for Papulopustular Rosacea (PHASE4)
- Comparison of Two Modes of Photodynamic Therapy for the Treatment of Actinic Keratosis on the Upper Extremities (PHASE4)
- Daylight Photodynamic Therapy for Actinic Keratosis (PHASE1)
- Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: